MAIA Biotechnology announces $2.25M private placement of stock and warrants

MAIA Biotechnology, Inc.

Gross proceeds ~$2.25M from sale of 1,733,766 shares at $1.30; one warrant per share at $1.57 exercise price.
Funds will support Step 1 of Part C of Phase II trial THIO-101 and working capital.
Greater than 5% holder FGMK subscribed for 769,230 shares & warrants for ~$1M; director Stan Smith for 19,230 shares.
Existing warrants for 1,396,667 shares amended to reduce exercise price from $1.87 to $1.30.
Closing expected on or about October 1, 2025.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.